Cellular Biomedicine Inc logo

CBMG - Cellular Biomedicine Inc News Story

$18.11 0.2  1.3%

Last Trade - 15/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £259.6m
Enterprise Value £275.7m
Revenue £238k
Position in Universe 3633rd / 6547

BRIEF-Cellular Biomedicine Says Cannot Accurately Predict Impact From Coronavirus

Fri 28th February, 2020 9:37pm
Feb 28 (Reuters) - Cellular Biomedicine Group Inc  CBMG.O :
    * CELLULAR BIOMEDICINE GROUP ANNOUNCES Q4 AND FULL YEAR 2019
FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS
    * CELLULAR BIOMEDICINE - FULL EXTENT TO WHICH CORONAVIRUS
WILL
NEGATIVELY IMPACT BUSINESS & RESULTS IS HIGHLY UNCERTAIN &
CANNOT BE ACCURATELY PREDICTED
    * CELLULAR BIOMEDICINE GROUP SAYS CO HAS EXPERIENCED, &
EXPECT TO
CONTINUE TO EXPERIENCE, A SLOWDOWN IN PATIENT RECRUITMENT FOR
CLINICAL STUDIES
    * CELLULAR BIOMEDICINE GROUP SAYS CO IS MINDFUL OF ONGOING
RISKS
POSED BY CORONAVIRUS DISEASE, OR COVID-19

Source text for Eikon:  ID:nPn2S22kca 
Further company coverage:  CBMG.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.